AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00823030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urodynamic study
Description: A small catheter will be inserted into the bladder and water will slowly be instilled through the catheter and into your bladder. A series of measurements will then be taken to assess your bladder's capacity to hold liquid, the average and maximum urine flow rates, as well as bladder filling and leak point pressure readings.
Study NCT00823030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 20 cc of alkalinized lidocaine will be injected after the first UDS
Study NCT00823030 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 20 cc of normal saline will be injected into the bladder after the first UDS
Study NCT01046045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Description: everolimus at an initial daily loading dose between 1 and 4 mg dose of everolimus will be adjusted to maintain a trough everolimus level between 5 and 12 ng/mL
Study NCT01356771 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Surveys & Mailed Materials
Description: Phase I: Patients are screened for their level of risk for skin cancer. They will complete a survey and undergo a skin exam administered by the research staff. Moderate- and high-risk persons will be invited to enroll in Phase II.~Phase II: Three sets of materials will be sent in the mail over the course of 6 weeks. Pamphlets will contain information about ways to reduce participant's risk of skin cancer, including sun protection practices, benefits of skin screening practices, and how to do skin self-examinations.~The participant will also complete two surveys for this study, one at baseline and then one at follow up approximately three months later.~Each survey will ask the participant about:~* Current and past skin cancer screening practices~* Current and past sun protection practices~* Attitudes about skin cancer and sun protection~* Knowledge of melanoma
Study NCT00458276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tezosentan
Description: Tezosentan (ACT-050089, Ro 61-0612) as a 1% solution in 0.9% NaCl (i.e., normal saline) for i.v. use.
Study NCT00458276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo (i.e., normal saline) for i.v. use.
Study NCT03640247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-narcotic group regimen
Description: Non-Narcotic Group. Receives only alternating acetaminophen and ibuprofen
Study NCT03640247 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Narcotic group regimen
Description: Narcotic Group: Alternating acetaminophen and ibuprofen, with a prescription of 10 tablets oxycodone (or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg) for break through pain.
Study NCT00455845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel IUD
Description: levonorgestrel IUD
Study NCT00455845 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Levonorgestrel IUD
Description: levonorgestrel IUD
Study NCT04486599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Navigation
Description: The echo-guided sclerotherapy procedure, assisted by electromagnetic navigation, will be carried out in a clean room during the day hospitalisation and followed by a control Echo-Doppler carried out 2 hours after the procedure.
Study NCT02704013 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxybutynin
Description: Anticholinergic
Study NCT06487663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE with ICI
Description: Transcatheter hepatic artery chemoembolization and immune checkpoint inhibitors
Study NCT04042077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Description: Powder for solution for infusion 300 mg or tablet 450 mg, BID, for 5 to 14 days
Study NCT04042077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Powder for solution for infusion 15mg/kg, BID, for 5 to 14 days
Study NCT04042077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Solution for infusion or tablet, 600 mg BID, for 5 to 14 days
Study NCT04042077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/Tazobactam
Description: Powder for solution for infusion 4/0.5 g, TID, for 5 to 14 days
Study NCT04042077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tigecycline
Description: Powder for solution for infusion 50 mg, TID, for 5 to 14 days
Study NCT01055236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydroxyzine
Description: 75 mg of hydroxyzine orally as premedication drugs at least half an hour before operation.
Study NCT03773913 — intervention group
Intervention type: OTHER
Intervention: ICBHSS model
Description: Bundle of evidence-based interventions that include the following 5 components:~1. Community engagement meetings and feedback;~2. Elimination of public sector facility user fees for children under five and pregnant women;~3. Pro-active community based IMCI using trained, equipped, supervised, and salaried Community Health Workers (CHWs) with additional services including linkage to family planning and counseling, HIV testing \& referrals;~4. Clinical mentoring and enhanced supervision by a trained peer coach at public sector facilities;~5. Basic infrastructure improvements and supply chain management training of pharmacy managers
Study NCT01530737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin III
Description: Patients randomized to receive Antithrombin concentrate will receive a dose of AT to achieve a target value of 1.2U/ml.
Study NCT01530737 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Patients randomized to the control group will receive a placebo consisting of normal saline in a volume equivalent to the volume of antithrombin the same patient in the treatment group would have received and administered by anesthesia and perfusion in the exact same manner as the AT is administered in the treatment group.
Study NCT02927912 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Electron Beam Therapy
Description: Undergo IOERT boost
Study NCT02927912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy
Description: Undergo lumpectomy
Study NCT02927912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02927912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02927912 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo whole breast radiation therapy
Study NCT02927912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstructive Surgery
Description: Undergo oncoplastic reconstruction
Study NCT01937975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg oral tablet administered once a day for 10 days
Study NCT01937975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: 50 mg oral tablet administered once a day for 10 days
Study NCT00276835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose interleukin-2
Description: Administered days 1-5, and 15-19; the patient will receive 600,000 IU/kg IL-2 by intravenous infusion over 15 minutes every 8 hours (on day 1 and day 15, patients will receive a maximum of 2 doses per day; on all other days in the cycle patients will receive a maximum of 3 doses per day)
Study NCT00276835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: genistein
Description: Starting on day 10 and continuing through day 19, genistein will be administered orally at a dose of 600mg/day in two divided doses (i.e. 300mg po bid x 10 days)
Study NCT03174665 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT01026129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Bolus dose of intravenous remifentanil 0,25 mcg/kg given once before emergence of general anesthesia.
Study NCT01026129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
Study NCT01026129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
Study NCT00711308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tinzaparin
Description: tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
Study NCT00711308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tinzaparin
Description: tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
Study NCT00711308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acenocoumarol
Description: acenocoumarol for 6 months
Study NCT01263509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and voglibose
Description: Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
Study NCT01263509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and voglibose
Description: Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
Study NCT02287233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be taken orally once daily.
Study NCT02287233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low-dose cytarabine will be administered subcutaneously on Days 1 to 10 of each 28-day cycle.
Study NCT04296747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction chemotherapy
Description: Toripalimab 240mg, d1; docetaxel 75mg/m2 d1; cisplatin 75mg/m2 d1, q21d, for 2 cycles
Study NCT04296747 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: After induction chemotherapy, patients with resectable hypopharyngeal cancer would accept surgery within 2-4 weeks and investigator-selected postoperative treatment
Study NCT04296747 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemoradiotherapy
Description: After induction chemotherapy, patients with unresectable hypopharyngeal cancer who achieved CR/PR/SD in the tumor evaluation according to RECIST1.1 would accept another cycle of chemotherapy, and then radical chemoradiotherapy with cisplatin 100mg/m2, q21d
Study NCT02127125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.
Study NCT02127125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic
Description: Synbiotic \[5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.
Study NCT02127125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer
Description: Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks
Study NCT03345745 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: salivary samples
Description: Salivary Hs-CRP, Fetuin-A and S100A12 levels and salivary flow rates were evaluated at baseline and a month after the treatments
Study NCT02019862 — intervention group
Intervention type: DEVICE
Intervention: TRJ® Total Hip Arthroplasty
Study NCT03014141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oat bran (Oatwell 28)
Description: 11 g oat bran containing 3.1 gram oat beta-glucan
Study NCT03014141 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 11 g of Maltodextrin
Study NCT03528382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation quality improvement system
Description: Cardiac rehabilitation quality improvement system is divided into two period. The period I of rehabilitation has three parts, including daily life, rehabilitation exercise training, publicity and education. And the period II of rehabilitation is based on aerobic exercise, as well as combined with resistance and flexibility exercises
Study NCT00405938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg IV every 2 weeks
Study NCT00405938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: anastrozole (1 mg orally daily)
Study NCT00405938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant).
Study NCT00572533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESA Dose Adjustment per standard Anemia Management Protocol
Description: Amount of ESA dose adjustment in Units per week guided by standard Anemia Management Protocol in use at the facility
Study NCT00572533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESA Dose Adjustment per Smart Anemia Manager Algorithm
Description: Amount of ESA dose adjustment in Units per week individualized to subject's dose-response profile guided by Smart Anemia Manager algorithm
Study NCT02638597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: FDA Approved Drug(s)/Biologic(s) (study use is not an FDA-approved use)
Study NCT02638597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation counseling
Description: smoking cessation counseling
Study NCT02638597 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: smoking cessation counseling
Description: smoking cessation counseling
Study NCT02353468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT02353468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02353468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT04771377 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplementation
Description: protein supplements will be supplied to participants at no cost physical activity Will be performed virtually by PT
Study NCT00848484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK5757
Description: This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 25 mg capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 MK5757 50 mg capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days
Study NCT00848484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 one placebo capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 two MK5757 placebo capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days.
Study NCT01587482 — intervention group
Intervention type: PROCEDURE
Intervention: PacLitaxel Eluting Balloon Application
Description: Stenting is a standard of care in revascularization for superficial femoral artery (SFA) atherosclerotic lesions. However, the Achilles' heel of this technique remains in-stent restenosis (ISR). While most of local therapies have failed to demonstrate significant benefit, studies for the treatment of SFA ISR are lacking and percutaneous transluminal angioplasty remains the current standard of care for this indication. Recent studies have shown successful results of drug eluting balloon in the treatment of SFA de-novo lesions and of coronary ISR.
Study NCT03151746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill administered orally 1 hour before planned surgical procedure
Study NCT03151746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin pill (1200mg) administered orally 1 hour before planned surgical procedure
Study NCT00758342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% + Brinzolamide 1.0%
Description: Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
Study NCT00758342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost 0.004% + Tears Natural
Description: Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
Study NCT03473210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: ampicillin 2g IV every 6hours for 48 hours, followed by erythromycin 250mg every 6hours for 5days
Study NCT03473210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: dexamethasone 8mg intramuscular every 12hours for 48 hours i.e. in four divided doses
Study NCT03473210 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniopatch
Description: a total of around 60-80 mL of platelets, 100-150 mL of FFP and 100-150 mL of amnioinfusion fluid was used throughout the procedure
Study NCT01937169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Task
Description: A motor task executed for 30 minutes after drug adminidtration
Study NCT01937169 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motor Task
Description: A motor task executed for 30 minutes after drug adminidtration
Study NCT01937169 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Levodopa tablet
Study NCT01937169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa tablet
Study NCT01937169 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham non-motor task
Description: A non-motor task )sham condition) will be executed for 30 minutes after drug adminidtration
Study NCT01937169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Study NCT00267098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Description: Biventricular pacing
Study NCT00267098 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronization Therapy (CRT)
Description: Right ventricular pacing
Study NCT01225497 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard eccentric exercise
Description: Participants stand with the balls of their feet on a step. They rise up onto tip toes using both legs then transfer onto the affected leg, then slowly lower their heel below the level of the step keeping their weight-bearing limb fully straight (eccentric phase). This constitutes 1 repetition and is repeated for 3 x 15 reps.~The previous procedure is then carried out with the knee bent during the eccentric phase of loading for 3 x 15 reps.~All of the above is carried out twice a day as per Alfredsons protocol. Participants are encouraged as per Alfredsons procedure to continue into discomfort not severe pain.
Study NCT01225497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eccentric exercise-Experimental group
Description: Eccentric exercise is performed the same as in the standard group. However participants in this group are encouraged to do the number of repetition they can manage so long as it is also to discomfort.
Study NCT04623606 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BOOST cells
Description: Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.
Study NCT03135990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy with Virtual Reality Technology
Description: Cognitive Behavioral Therapy Intervention: This manualized intervention is a modified version of the Unified Protocol for Emotional Disorders in Youth, a modular Cognitive Behavioral Therapy protocol for anxiety disorders and depression with demonstrated efficacy in youth. The 10-session intervention includes psychoeducation about anxiety disorders and their treatment (1 session), emotion awareness and regulation (2 sessions), exposure therapy using virtual reality environments (6 sessions), and review and relapse prevention (1 session). All treatment sessions will be videotaped to ensure fidelity to treatment manual and modules.
Study NCT02853487 — intervention group
Intervention type: DEVICE
Intervention: Actigraphy
Description: An actigraph from Philips
Study NCT02853487 — intervention group
Intervention type: OTHER
Intervention: Diary
Description: Questions on sleep times and awakenings and attacks in the morning and evening for 2 weeks.
Study NCT03400683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 200 microgram misoprostol in sublingual every four hours for a maximum of five doses
Study NCT03400683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 15mg( letrozole 2.5mg) on three successive day
Study NCT03400683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foley's catheter
Description: transcervical 16F Foley's catheter with 30 ml balloon capacity inserted under aseptic conditions